GC Biopharma Corp. (KRX:006280)

South Korea flag South Korea · Delayed Price · Currency is KRW
126,000
-3,300 (-2.55%)
Last updated: May 27, 2025
13.11%
Market Cap 1.43T
Revenue (ttm) 1.71T
Net Income (ttm) 28.73B
Shares Out 11.41M
EPS (ttm) 2,517.06
PE Ratio 49.78
Forward PE 109.53
Dividend 1,500.00 (1.20%)
Ex-Dividend Date Dec 27, 2024
Volume 21,551
Average Volume 24,823
Open 127,800
Previous Close 129,300
Day's Range 125,800 - 129,100
52-Week Range 110,100 - 181,800
Beta 1.41
RSI 53.05
Earnings Date May 15, 2025

About GC Biopharma

GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea and internationally. It provides over-the-counter drugs, such as Acustop Cataplasma for Analgesic and anti-inflammatory effect; Kenhancer plaster for anti-inflammatory; and Zenol Cool Type and Zenol Mild Hot Type drugs to treat anti-inflammatory and pain relief. The company also offers Albumin-GCC injection (inj.) for hypoalbuminemia and shock in acute hemorrhage, as well as low synthesis of albumin; Antithrombin-III (AT-III) inj. for heredit... [Read more]

Sector Healthcare
Founded 1967
Employees 2,009
Stock Exchange Korea Stock Exchange
Ticker Symbol 006280
Full Company Profile

Financial Performance

In 2024, GC Biopharma's revenue was 1.68 trillion, an increase of 3.27% compared to the previous year's 1.63 trillion. Losses were -26.28 billion, -1.32% less than in 2023.

Financial Statements

News

There is no news available yet.